Siemens Group Forms the World's First Full Service Diagnostics

SIEMENSSiemens has been given the green light to acquire the diagnostics division of Bayer Healthcare without restrictions. The approval was granted yesterday by the European Commission, following the earlier approval by U.S. antitrust authorities at the beginning of October. This follows the acquisition of the U.S. firm Diagnostic Products Corporation (DPC), which was completed at the end of July. Upon completion of the Bayer acquisition, which is expected by early 2007, both companies will be merged and will operate as "Siemens Medical Solutions Diagnostics," an U.S.-based subsidiary and part of Siemens Medical Solutions.

"This has paved the way for Siemens to create the world's first full service diagnostics company," explained Prof. Dr. Erich R. Reinhardt, member of the Managing Board of Siemens AG and president and CEO of Siemens Medical Solutions (Med), following the Commission's decision. The successful entry into the in-vitro diagnostics market will allow the company to combine the entire imaging diagnostics, laboratory diagnostics and clinical information technology value chain under one roof and offer its customers customized solutions. "This will further improve the quality and efficiency of healthcare," commented Reinhardt.

The purchase price for Bayer Diagnostics is roughly EUR 4.2 billion; in fiscal 2005 the Group generated sales of EUR 1.4 billion and a double-digit profit margin related to earnings before interest, tax, depreciation and amortization (EBITDA). The acquisitions of Bayer Diagnostics and DPC (the latter completed in July for a purchase price of US$1.86 billion) will make Siemens Medical Solutions No. 2 worldwide in immunodiagnostics. Bayer Diagnostics is also a world market leader in clinical chemistry with a leading position in near-patient testing, laboratory automation and hematology (blood cell diagnostics). In addition, the acquisition of Bayer Diagnostics will enable the Siemens Group to tap the rapidly growing market for molecular diagnostics based on gene analysis (nucleid acid testing).

"Molecular medicine has huge potential to detect diseases such as cancer at a much earlier stage than what is possible today," said Reinhardt. "Molecular medicine is already helping physicians choose suitable medications for a particular patient, predict the effects of those medications and personalize patients' treatments. The long-term vision is to identify and treat the molecular causes of diseases long before the patient ever experiences any symptoms, and Siemens is at the forefront of developing these molecular medicine solutions that will transform the future of healthcare."

Sales of Bayer Diagnostics rose in 2005 by 8.4 percent to EUR 1.4 billion. The division offers an extensive portfolio of in-vitro diagnostic products for evaluating and monitoring the therapy of numerous diseases, including cardiovascular disorders, kidney diseases, infections, cancer and diabetes. The business units are Laboratory Testing, including the ADVIA Centaur(R), Centaur(R) CP and Centaur(R) XP, ADVIA(R) Clinical Chemistry, ADVIA(R) LabCell(R) and WorkCell(R) Automation, ADVIA(R) Hematology and Clinitek(R) Atlas systems; Near Patient Testing with its Rapidpoint(R), Rapidlab(R), RapidComm(TM) and Clinitek(R) brands; and Molecular Testing with its Trugene(R) and Versant(R) lines of tests and systems.

About Siemens Medical Solutions
Siemens Medical Solutions (Med) (NYSE:SI) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. From imaging systems for diagnosis, to therapy equipment for treatment, to patient monitors to hearing instruments and beyond, Siemens innovations contribute to the health and well-being of people across the globe, while improving operational efficiencies and optimizing workflow in hospitals, clinics, home health agencies and doctors' offices. Employing approximately 33,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.6 billion EUR, orders of 8.6 billion EUR and Group profit of 976 million EUR for fiscal 2005 (September 30).
http://www.medical.siemens.com/

Most Popular Now

Health Fabric and Sandwell Council Secur…

Digital health company Health Fabric is preparing to work with Sandwell Council after learning that it has secured support from The Healthy Ageing Challenge. The company will work with public health...

Philips Highlights AI-Powered Precision …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, showcases its award-winning AI-powered systems and solutions debuting at the European Congress of Radiology (ECR, July 13-17, Vienna...

Could a Computer Diagnose Alzheimer's Di…

It takes a lot of time - and money - to diagnose Alzheimer's disease. After running lengthy in-person neuropsychological exams, clinicians have to transcribe, review, and analyze every response in...

Siemens Healthineers Accelerates and Imp…

Siemens Healthineers presents functionalities powered by Artificial Intelligence (AI) that accelerate and improve Magnetic Resonance Imaging (MRI). The quality of MR imaging is defined by the trade-off between scan time...

Building the Right Foundations to Delive…

Opinion Article by Gary Birks, Gary Birks, General Manager, UK and Ireland, Orion Health. The latest strategy for health and care IT looks to build on what has been achieved over...

Using Technology to Support Primary Care

Opinion Article by Paul Bensley, Managing Director of Primary Care Cloud Telephony Specialist X-on. It is good to see the publication of this strategy [A plan for digital health and social...

A Machine Learning Model to Predict Immu…

Immunotherapy is a new cancer treatment that activates the body's immune system to fight against cancer cells without using chemotherapy or radiotherapy. It has fewer side effects than conventional anticancer...

Virtual Reality App Trial Shown to Reduc…

Results from a University of Otago, Christchurch trial suggest fresh hope for the estimated one-in-twelve people worldwide suffering from a fear of flying, needles, heights, spiders and dogs. The trial, led...

Two Leading CIOs Join the Highland Marke…

Two of the NHS' most dynamic chief information officers have joined Highland Marketing’s advisory board of NHS IT professionals and health tech industry experts. Ian Hogan, a CIO at the Northern...

Teaching AI to Ask Clinical Questions

Physicians often query a patient's electronic health record for information that helps them make treatment decisions, but the cumbersome nature of these records hampers the process. Research has shown that...

AI Analyses Neuron Changes to Detect whe…

A research group from Nagoya University in Japan has developed an artificial intelligence (AI) for analyzing cell images that uses machine learning to predict the therapeutic effect of drugs. Called...

MIT Engineers Develop Stickers that can …

Ultrasound imaging is a safe and noninvasive window into the body’s workings, providing clinicians with live images of a patient’s internal organs. To capture these images, trained technicians manipulate ultrasound...